Tumor M2-Pyruvate Kinase, Matrix Carbonic Anhydrase IX, and Metalloproteinase 9 — Novel Prognostic Markers of Renal Cell Carcinoma

Amoev Z.V., Alyasova A.V., Gorshkova T.N., Samsonova E.I., Strokina E.V., Kontorshchikova K.N.

Key words: tumor M2-pyruvate kinase; matrix carbonic anhydrase IX; metalloproteinase 9; renal cell carcinoma; markers of renal cell carcinoma.

2020, volume 12, issue 2, page 43.

DOI: https://doi.org/10.17691/stm2020.12.2.05

Full text

html pdf

1592

2127

Abstract
References
How to cite

The aim of the study was to assess the possibility of using plasma levels of tumor M2-pyruvate kinase (Tu M2-PK), matrix carbonic anhydrase IX (CA9), and matrix metalloproteinase 9 (MMP9) in patients with renal cell cancer as predictors of the disease course and the response to treatment.

Materials and Methods. Samples of blood plasma or serum of 46 patients with clear cell renal cancer T_1–4N_0–1M_0–1 obtained before surgery and 8–9 days after surgery were tested. The control group consisted of 20 practically healthy individuals, comparable in age with the examined patients. Quantitative determination of Tu M2-PK in EDTA-added blood plasma was performed by enzyme-linked immunosorbent assay using a ScheBo Tumor M2-PK test (Germany). Determination of CA9 by ELISA was performed using a Human Carbonic Anhydrase IX Quantikine ELISA Kit (USA) and MMP9 — using a Quantikine ELISA Kit (USA).

Results. In patients with renal cell carcinoma, a statistically significant increase in the level of Tu M2-PK, CA9 and a statistically significant decrease in MMP9 in comparison with the control group were found. The level of Tu M2-PK in patients with localized kidney cancer was significantly lower than in patients with disseminated cancer. An increase in size of the primary tumor and a decrease in the degree of its differentiation correlated with an increase in Tu M2-PK, and decrease in CA9 and MMP9 in the blood serum. Performing surgery equivalent to nephrectomy did not change the Tu M2-PK levels in the early postoperative period, but caused a decrease in the levels of CA9 and MMP9.

Conclusion. The results indicate a potential significance of Tu M2-PK, CA9, and MMP9 as biological markers for predicting the disease course in patients with renal cell carcinoma.

Perevodchikova N.I., Gorbunova V.A. Rukovodstvo po khimioterapii opukholevykh zabolevaniy [Guidelines for chemotherapy for tumor diseases]. Moscow: Prakticheskaya meditsina; 2017.
Lazarev S.M., Massard Zh., Reshetov A.V., Nikolaev G.V., Volgin G.N., Osipov E.V., Lomteva E.Yu., Nokhrin A.V., Kakysheva O.E. The role of oncomarkers CEa, Cyfra-21, NSE, Tu M2-PK in diagnosis and treatment of lung cancer. Vestnik hirurgii im. I.I. Grekova 2010; 1(169): 39–43.
Kler Kh.U., Khardt P., Aygenbrodt Kh.E. New tumor marker: metabolic tumor marker Tu M2-PK. Klinicheskie perspektivy v gastroenterologii, gepatologii 2001; 6: 12–15.
Movsesyan V.V. Diagnosticheskaya znachimost’ opukholevogo markera TuM2-РK pri novoobrazovaniyakh pochki. Avtoref. … dis. kand. med. nauk [Diagnostic significance of the tumor marker TuM2-RK in kidney tumors. PhD Thesis]. Moscow; 2007.
Oosterwijk-Wakka J.C., Boerman O.C., Mulders P.F., Oosterwijk E. Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma. Int J Mol Sci 2013; 14(6): 11402–11423, https://doi.org/10.3390/ijms140611402.
Leibovich B.C., Sheinin Y., Lohse C.M., Thompson R.H., Cheville J.C., Zavada J., Kwon E.D. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol 2007; 25(30): 4757–4764, https://doi.org/10.1200/jco.2007.12.1087.
Gorban’ N.A., Popov A.M., Karyakin O.B. Prognostic value of the expression of carbonic anhydrase 9 in combination with other markers in patients with clear cell renal cell carcinoma. Onkourologia 2016; 12(3): 40–44, https://doi.org/10.17650/1726-9776-2016-12-3-40-44.
Pasechnik D.G., Kogan M.I., Akhokhov Z.M. The features of expression and prognostic significance of the peptide molecules connected with the key properties of renal cell carcinoma. Urologicheskie vedomosti 2017; 7(4): 5–16, https://doi.org/10.17816/uroved745-16.
Rogova L.N., Shesternina N.V., Zamechnik T.V., Fastova I.A. Matrix metalloproteinases, their role in physiological and pathological processes (review). Vestnik novyh medicinskih tehnologij 2011; 18(2): 86–89.
Cherdantseva T.M., Bobrov I.P., Varlamov S.V., Myadelets M.N., Klimachev I.V., Avdalyan A.M., Ganov D.I., Lazarev A.F. Prognostic value of matrix metalloproteinase 9 in renal cell carcinoma. Onkourologiya 2018; 14(3): 17–24, https://doi.org/10.17650/1726-9776-2018-14-3-17-24.
Kolbanov K.I., Trakhtenberg A.Kh., Frank G.A., Zavalishina L.E., Boyko A.V., Pikin O.V., Glushko V.A. Prognostic factors, results of surgical and combination treatments in patients with different morphological types of non-small cell lung carcinoma. Onkologiya. Zhurnal im. P.A. Gertsena 2013; 2(3): 11–16.
Shaco-Levy R., Sharabi S., Benharroch D., Piura B., Sion-Vardy N. Matrix metalloproteinases 2 and 9, E-cadherin, and beta-catenin expression in endometriosis, low-grade endometrial carcinoma and non-neoplastic eutopic endometrium. Eur J Obstet Gynecol Reprod Biol 2008; 139(2): 226–232, https://doi.org/10.1016/j.ejogrb.2008.01.004.
Bui M.H., Seligson D., Han K.R., Pantuck A.J., Dorey F.J., Huang Y., Horvath S., Leibovich B.C., Chopra S., Liao S.Y., Stanbridge E.J., Lerman M.I., Palotie A., Figlin R.A., Belldegrun A.S. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003; 9(2): 802–811.
Ganusevich I.I. The role of matrix metalloproteinases (MMP) in malignant neoplasms. II. The participation of MMPs in angiogenesis, invasion and metastasis of tumors. Onkologіa 2010; 12(2): 108–117.
Ingels A., Hew M., Algaba F., de Boer O.J., van Moorselaar R.J., Horenblas S., Zondervan P., de la Rosette J.J., Pilar Pes Laguna M. Vimentin over-expression and carbonic anhydrase IX under-expression are independent predictors of recurrence, specific and overall survival in non-metastatic clear-cell renal carcinoma: a validation study. World J Urol 2017; 35(1): 81–87, https://doi.org/10.1007/s00345-016-1854-y.
Shchukin D.V., Lesovoy V.N., Yakovtsova I.I., Danilyuk S.V. The activity of matrix metalloproteinase-9 (MMP-9) with intravenous spread of renal cell carcinoma. Visnik problem biologii i medicini 2015; 1(2): 283–290.
Avdoshin V.P., Kotelnikova E.V., Babichenko I.I. Diagnostic and prognostic importance of Ki-67, MMP-9 and collagen IV immunohistochemical markers in bladder tumors. Vestnik Rossiiskogo universiteta druzhby narodov. Seriya: Meditsina 2011; 4: 80–86.
Wechsel H.W., Petri E., Bichler K.H., Feil G. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK). Anticancer Res 1999; 19(4A): 2583–2590.

Amoev Z.V., Alyasova A.V., Gorshkova T.N., Samsonova E.I., Strokina E.V., Kontorshchikova K.N. Tumor M2-Pyruvate Kinase, Matrix Carbonic Anhydrase IX, and Metalloproteinase 9 — Novel Prognostic Markers of Renal Cell Carcinoma. Sovremennye tehnologii v medicine 2020; 12(2): 43, https://doi.org/10.17691/stm2020.12.2.05